- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Glenmark Pharmaceuticals Ltd spurts 3.28% | 2 | capitalmarket.com | ||
| 09.04. | Glenmark Gets FDA Approval for Bioequivalent Progesterone Vaginal Insert | 6 | Contract Pharma | ||
| 09.04. | Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg | 873 | PR Newswire | ELMWOOD PARK, N.J., April 9, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Limited (Glenmark) has received final approval from the United States Food & Drug Administration... ► Artikel lesen | |
| 09.04. | Glenmark Pharma gets USFDA nod for Progesterone Vaginal Inserts | 5 | capitalmarket.com | ||
| 02.04. | Glenmark goes direct with new US Ryaltris marketing plan as it drops partner model | 5 | FiercePharma | ||
| 01.04. | Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS in the U.S., Significantly Expanding Its Innovative Portfolio | 150 | PR Newswire | RYALTRIS® is Glenmark's first innovative product introduced into the U.S. market
ELMWOOD PARK, N.J., April 1, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc.... ► Artikel lesen | |
| 31.03. | Glenmark Pharmaceuticals Canada Inc. Launches Men's GLN-Minoxidil 5% w/w Topical Aerosol Foam in Canadian Retail | 329 | PR Newswire | GLN-Minoxidil Men's 5% Foam is a topical treatment formulated with 5% minoxidil, a widely used and clinically established ingredient for supporting hair regrowth in men. The fast-drying, unscented aerosol... ► Artikel lesen | |
| 24.03. | Glenmark Pharma may outperform amid market correction; technicals turn positive: Ruchit Jain | 4 | Times of India | ||
| GLENMARK PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 21.03. | Glenmark Pharma launches GLIPIQ (semaglutide) in India for Type 2 Diabetes at lower cost | 3 | capitalmarket.com | ||
| 19.03. | Glenmark secures USFDA nod for OTC Nasal Spray; launches Generic Milnacipran tablets in US | 3 | capitalmarket.com | ||
| 16.03. | Glenmark Pharma gains as US arm to launch Potassium Phosphates Injection | 2 | capitalmarket.com | ||
| 05.03. | FDA gives Glenmark thumbs up for first 'true' generic version of GSK's asthma inhaler Flovent | 4 | FiercePharma | ||
| 04.03. | Glenmark Gets FDA Nod for Fluticasone Propionate Inhalation Generic | 2 | Contract Pharma | ||
| 04.03. | Glenmark Pharmaceuticals: Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity | 243 | PR Newswire | ELMWOOD PARK, N.J., March 4, 2026 /PRNewswire/ -- Glenmark Specialty SA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S.... ► Artikel lesen | |
| 04.03. | Glenmark Pharma secures USFDA nod for Fluticasone Propionate Inhalation Aerosol | 7 | capitalmarket.com | ||
| 04.03. | Glenmark Wins US FDA Approval For Inhalation Therapy Medicine With 180 Day Generic Exclusivity | 4 | The Free Press Journal | ||
| 27.02. | Glenmark Pharma's USA arm to market Sodium Phosphate injection in April 2026 | 3 | capitalmarket.com | ||
| 26.02. | Glenmark Pharmaceuticals Ltd gains for third straight session | 2 | capitalmarket.com | ||
| 22.01. | EQS-News: AcuCort AB: AcuCort schließt kommerzielle Vereinbarung mit Glenmark Pharmaceuticals für Deutschland und fünf weitere europäische Länder | 515 | EQS Group (DE) | EQS-News: AcuCort AB
/ Schlagwort(e): Joint Venture/Produkteinführung
AcuCort schließt kommerzielle Vereinbarung mit Glenmark Pharmaceuticals für Deutschland und fünf weitere... ► Artikel lesen | |
| 22.01. | AcuCort Signs Glenmark Deal To Market Zeqmelit In Six European Countries | 6 | RTTNews |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SINOPHARM | 2,060 | +2,79 % | SINOPHARM (01099): ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE FIRST QUARTER ENDED 31 MARCH ... | ||
| CSPC PHARMA | 0,892 | -1,37 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORISATION APPLICATION FOR AMPHOTERICIN B LIPOSOMAL, POWDER FOR CONCENTRATE FOR DISPERSION ... | ||
| WUXI BIOLOGICS | 3,655 | +1,11 % | WUXI BIO (02269): SUSTAINABILITY REPORT 2025 | ||
| SHANGHAI FOSUN PHARMACEUTICAL | 2,239 | +4,63 % | Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution | SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter... ► Artikel lesen | |
| GEDEON RICHTER | 34,860 | -0,97 % | Gedeon Richter Plc.: Extraordinary Information | ||
| DR REDDYS | 11,800 | +2,61 % | Dr. Reddy Falls Despite OK From Health Canada | ||
| ASPEN PHARMACARE | 7,000 | -1,41 % | ASPEN PHARMACARE HOLDINGS LIMITED - Results of the general meeting | ||
| SHANGHAI PHARMACEUTICALS | 1,170 | -4,88 % | SH PHARMA 1Q26 Attributable Net Profit Up 6.35% YoY | ||
| LUYE PHARMA | 0,288 | 0,00 % | LUYE PHARMA (02186): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | ||
| SIHUAN PHARMACEUTICAL HOLDINGS GROUP | 0,139 | -0,71 % | SIHUAN PHARM (00460): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDER | ||
| CHINA RESOURCES PHARMACEUTICAL | 0,585 | +2,63 % | CHINARES PHARMA Subsidiary Completes Phase III Clinical Trial Registration Disclosure for Diabetes Injection | ||
| HANSOH PHARMACEUTICAL | 3,914 | -3,71 % | HANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 ... | ||
| CHINA SHINEWAY PHARMACEUTICAL GROUP | 1,090 | +2,83 % | SHINEWAY PHARM (02877): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF 2025 ANNUAL REPORT, CIRCULAR, NOTICE OF THE ANNUAL ... | ||
| KALBE FARMA | 0,036 | 0,00 % | KLBF profit rises 13% in 2025, prepares IDR 500 billion buyback: Strong export lifts KLBF's net profit 13% to ... | ||
| BAYER | 36,450 | -0,46 % | SCHOCK und CHANCE: Nel ASA, K+S und Bayer-Partner MustGrow! Welche Aktie überzeugt? | Wann startet endlich die Aktie von MustGrow durch? Eigentlich kann dies nur eine Frage der Zeit sein. Die Kanadier ersetzen konventionellen Dünger durch Senf. In den USA hat man bereits Zulassungen... ► Artikel lesen |
GLENMARK PHARMACEUTICALS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLENMARK PHARMACEUTICALS LTD finden Sie auf Wallstreet Online.